- AU$104.97m
- AU$73.16m
- AU$2.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.33 | ||
| Price to Tang. Book | 3.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 49.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.44% | ||
| Return on Equity | -32.47% | ||
| Operating Margin | -246.3% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0 | 0.01 | 0 | 0.05 | 2.1 | n/a | n/a | 2041.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is developing and commercializing therapies that address significant unmet medical needs. The Company is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The Company is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The Company's subsidiary is LTR Pharma Inc.
Directors
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- October 7th, 2020
- Public Since
- December 11th, 2023
- No. of Shareholders
- 3,285
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 180,977,728
- Address
- 9/204 Alice Street,, BRISBANE, 4000
- Web
- https://www.ltrpharma.com/
- Phone
- +61 800519711
- Auditors
- William Buck
Upcoming Events for LTP
Similar to LTP
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Ltr Pharma share price?
As of Today at 21:48 UTC, shares in Ltr Pharma are trading at AU$0.58. This share price information is delayed by 15 minutes.
How has the Ltr Pharma share price performed this year?
Shares in Ltr Pharma last closed at AU$0.58 and the price had moved by -66.67% over the past 365 days. In terms of relative price strength the Ltr Pharma share price has underperformed the ASX All Ordinaries Index by -69.72% over the past year.
What are the analyst and broker recommendations for Ltr Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Ltr Pharma dividend yield?
Ltr Pharma does not currently pay a dividend.
Does Ltr Pharma pay a dividend?
Ltr Pharma does not currently pay a dividend.
When does Ltr Pharma next pay dividends?
Ltr Pharma does not currently pay a dividend.
How do I buy Ltr Pharma shares?
To buy shares in Ltr Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ltr Pharma?
As of the previous close price of AU$0.58, shares in Ltr Pharma had a market capitalisation of AU$104.97m.
Where are Ltr Pharma shares listed?
Here are the trading details for Ltr Pharma:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: LTP
What kind of share is Ltr Pharma?
Based on an overall assessment of its quality, value and momentum Ltr Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ltr Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Ltr Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ltr Pharma. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -9.91%.
As of the last closing price of AU$0.58, shares in Ltr Pharma were trading +10.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ltr Pharma PE Ratio?
The Ltr Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ltr Pharma?
We do not have data on Ltr Pharma's directors